← All trials
NCT04999384
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Aug 10, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 31
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Adlai Nortye Biopharma Co., Ltd.Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.